Reading the Wegovy brochure: what the patient information actually tells you

Step 1, Understanding what the leaflet is and why it exists

Before you open the outer box, it helps to know what you are holding. The Patient Information Leaflet is not a marketing document; it is a regulatory requirement. The MHRA reviews and approves the wording, and Novo Nordisk must update it any time new safety information emerges. That is why the language is precise rather than warm, it is written to be accurate under scrutiny, not to be easy reading over a cup of tea.

The leaflet covers six standard sections: what Wegovy is and what it is for; what you need to know before using it; how to use it; possible side effects; storage; and the contents of the pack. Each section answers a specific question a patient or carer is likely to have.

A question our prescribers hear most weeks is whether the leaflet overrides what they have been told in a consultation. It does not. The PIL gives population-level information based on clinical trial data across thousands of patients. Your prescriber's instructions are tailored to you specifically, and in any conflict, follow your prescriber and contact them or the service to clarify. The full Wegovy treatment overview on this site covers how that clinical relationship works in practice.

Step 2, What the brochure says about who Wegovy is for

The PIL's eligibility section maps directly to Wegovy's UK licence. Semaglutide for weight management is approved for adults aged 18 and over with a BMI of 30 kg/m² or higher, or a BMI between 27 and 29.9 alongside at least one weight-related condition, such as high blood pressure, which is one of the conditions that can qualify you for Wegovy and that semaglutide may itself affect, high cholesterol, type 2 diabetes or obstructive sleep apnoea. The leaflet also lists groups who should not use Wegovy: people who are pregnant, breastfeeding or trying to conceive, those under 18, and anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

There is a section on other medicines and interactions. Because semaglutide slows gastric emptying, it can affect how quickly other oral medicines are absorbed. The leaflet flags this in general terms; your prescriber will check your full medicine list. One interaction worth knowing: women taking oral contraceptives are advised to discuss their method with their prescriber, since absorption timing may be relevant. The semaglutide information page goes deeper on this point.

The brochure notes that lower BMI thresholds may apply for some ethnic backgrounds under UK clinical guidance, though the specific adjustments are typically discussed at consultation rather than printed in the PIL itself. NICE's appraisal of semaglutide for weight management, NICE TA875, provides the formal framework clinicians follow.

Step 3, Dose schedule and how-to-use sections

The dose schedule section of the Wegovy PIL describes a step-by-step titration: the starting dose of 0.25mg weekly is a tolerability phase, meaning its purpose is to let the body adjust rather than to produce significant weight change. From there the schedule increases through 0.5mg, 1.0mg, 1.7mg and up to the maintenance dose of 2.4mg, spending roughly four weeks at each level. The MHRA's April 2026 approval of a higher-dose 7.2mg pen means that a further titration pathway now exists; the relevant PIL for that pen format carries the updated instructions.

The how-to-use section walks through the injection technique in numbered steps with diagrams: choosing an injection site (abdomen, thigh or upper arm), rotating the site each week, removing the pen cap, and confirming the dose window before injecting. It also describes what to do if a dose is missed, generally, take it as soon as you remember if there are still four or more days before your next scheduled dose, otherwise skip and continue on the usual day. For precise guidance in your own situation, your prescriber or the frequently asked questions page is the right starting point.

Storage instructions in the leaflet specify refrigeration at 2–8°C. There is a limited window during which an in-use pen can be kept at room temperature; the exact number of days is printed in the current PIL and varies by pack, so rather than quoting a figure here, check the leaflet in your box. If you are curious about Wegovy's 0.25mg starter pen, that page covers what to expect in the first four weeks.

Step 4, Side effects the leaflet lists and when to seek urgent help

The side effects section of the Wegovy brochure is the part most patients read first, and the longest. The most common effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and indigestion tend to be most noticeable when a dose increases and usually settle within one to two weeks as the body adapts. Fatigue, headache, dizziness and injection-site reactions also appear in the common-effects list.

Certain symptoms require urgent medical attention rather than watchful waiting. The MHRA has specifically highlighted acute pancreatitis as a known but infrequent serious risk: severe abdominal pain that persists and may spread to the back, with or without vomiting, needs same-day medical review. The leaflet also flags gallbladder symptoms, signs of dehydration from prolonged vomiting or diarrhoea, and symptoms of a serious allergic reaction. If any of these arise, the instruction is clear: stop the injection and contact a doctor or emergency service immediately. You can report any suspected side effect directly through the MHRA Yellow Card scheme.

Some patients also ask about the brown discolouration that can sometimes appear in a Wegovy pen, which our dedicated page explains in full. For broader questions about how semaglutide fits into weight management, the weight-loss treatment overview sets the fuller picture, and patients who have questions about the effect Wegovy may have on eye pressure will find a dedicated explanation there. If you'd like to explore whether Wegovy could be appropriate for your circumstances, you are welcome to start a free consultation, a GPhC-registered prescriber reviews every application the same day.